Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial

BACKGROUND: Ceftolozane/tazobactam is approved for treatment of hospital-acquired/ventilator-associated bacterial pneumonia (HABP/VABP) at double the dose approved for other infection sites. Among nosocomial pneumonia subtypes, ventilated HABP (vHABP) is associated with the lowest survival. In the A...

Descripción completa

Detalles Bibliográficos
Autores principales: Timsit, Jean-François, Huntington, Jennifer A., Wunderink, Richard G., Shime, Nobuaki, Kollef, Marin H., Kivistik, Ülo, Nováček, Martin, Réa-Neto, Álvaro, Martin-Loeches, Ignacio, Yu, Brian, Jensen, Erin H., Butterton, Joan R., Wolf, Dominik J., Rhee, Elizabeth G., Bruno, Christopher J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8356211/
https://www.ncbi.nlm.nih.gov/pubmed/34380538
http://dx.doi.org/10.1186/s13054-021-03694-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8356211/
https://www.ncbi.nlm.nih.gov/pubmed/34380538
http://dx.doi.org/10.1186/s13054-021-03694-3

Ejemplares similares